Core Viewpoint - In the context of profound changes in the pharmaceutical industry, HaiTe Biopharma is adopting a dual-track strategy of "innovation and imitation" to navigate through policy and market fluctuations, aiming to capture opportunities amid challenges [2]. Group 1: Company Strategy - HaiTe Biopharma has successfully launched two national class I new drugs and recognizes the significant impact of policies and funding on the pharmaceutical industry [3]. - The company is expanding its product line to include generic drugs in response to market changes and aims to participate in national procurement to quickly enter the chemical drug market [3][4]. - The company employs an open collaboration strategy for innovative drug development, working with top scientists, research institutions, and investing in biotech companies with potential [4][5]. Group 2: Investment Standards - HaiTe Biopharma has established three key standards for external investments: alignment with industry technology trends, strategic synergy with existing drug areas, and feasibility and commercialization potential of the technology [5][6]. - The company focuses on investing in cell and gene therapy (CGT) technologies, which are seen as the next significant direction in drug development [5][6]. - The investment strategy emphasizes the importance of addressing unmet clinical needs, particularly in oncology and neurological diseases, where there is substantial patient demand and limited existing therapies [7]. Group 3: Market Positioning - The company aims to solidify its current position in the generic drug market while pursuing innovative drugs and frontier investments for future growth [7]. - HaiTe Biopharma's approach reflects a strategic positioning to transition from high-speed growth to high-quality development, focusing on true innovation rather than mere imitation [7].

Core Insights - The event highlighted the growing importance of the global oil market and the role of Chinese derivatives in it [1][3] - The participation of over 110 representatives from more than 40 major oil companies and financial institutions indicates strong interest and engagement in the sector [1][3] Group 1: Event Overview - The Asia-Pacific Petroleum Conference (APPEC) hosted a global oil market seminar in Singapore, organized by Galaxy Futures, Galaxy Overseas, and the Shanghai International Energy Exchange [1] - This marks the second consecutive year that Galaxy Futures has held an in-depth oil market conference in Singapore [1] Group 2: Key Discussions - Experts discussed opportunities in the Chinese derivatives market, macroeconomic trends between China and the U.S., and the global oil market landscape [3] - Presentations included insights on the stable operation of Shanghai crude oil futures and the progress of natural gas futures listings [3] - A macroeconomic analysis was provided regarding the U.S.-China tariff negotiations and investment outlook [3] Group 3: Company Positioning - Galaxy Futures, a wholly-owned subsidiary of Galaxy Securities, has been engaged in international business since 2010 and has maintained a leading position in the industry since the launch of crude oil futures in 2018 [4] - The company is enhancing its technology, trading, delivery, and risk control to meet the diverse needs of overseas clients [4] - Future plans include providing cross-border services and solutions for both Chinese and global markets, along with educational initiatives to inform foreign investors about the Chinese futures market [4]